dexlansoprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiulcer, benzimidazole derivatives 4162 138530-94-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexlansoprazole sesquihydrate
  • R-Lansoprazole
  • (R)-Lansoprazole
  • dexlansoprazole
  • kapidex
  • dexilant
  • TAK-390
  • TAK-390MR
Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
  • Molecular weight: 369.36
  • Formula: C16H14F3N3O2S
  • CLOGP: 2.79
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 67.87
  • ALOGS: -3.17
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 30, 2009 FDA TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 808.63 13.54 426 31452 39345 50533901
Renal injury 232.69 13.54 112 31766 8499 50564747
End stage renal disease 229.17 13.54 98 31780 5639 50567607
Enthesopathy 192.67 13.54 93 31785 7100 50566146
Tenosynovitis 185.95 13.54 103 31775 10462 50562784
Blood parathyroid hormone decreased 160.93 13.54 82 31796 7032 50566214
Tongue disorder 154.43 13.54 87 31791 9129 50564117
Panniculitis 149.92 13.54 83 31795 8420 50564826
Red blood cell sedimentation rate 149.00 13.54 63 31815 3523 50569723
Blood pressure systolic increased 146.96 13.54 144 31734 35305 50537941
Rheumatoid nodule 140.57 13.54 92 31786 12643 50560603
Granuloma skin 134.34 13.54 68 31810 5750 50567496
Tendonitis 131.32 13.54 98 31780 16607 50556639
Skin necrosis 131.04 13.54 83 31795 10784 50562462
Ulcer 110.83 13.54 96 31782 20104 50553142
Alanine aminotransferase abnormal 103.10 13.54 51 31827 4105 50569141
Fear of injection 100.58 13.54 57 31821 6046 50567200
Skin ulcer 89.78 13.54 111 31767 35207 50538039
Hypercalcaemia 84.21 13.54 88 31790 23264 50549982
Incorrect product administration duration 83.32 13.54 59 31819 9216 50564030
Inflammation 82.68 13.54 137 31741 56775 50516471
Drug eruption 78.13 13.54 85 31793 23521 50549725
Basal cell carcinoma 77.13 13.54 84 31794 23272 50549974
Psoriatic arthropathy 76.21 13.54 119 31759 46913 50526333
Total lung capacity increased 75.46 13.54 25 31853 702 50572544
C-reactive protein abnormal 73.26 13.54 89 31789 27720 50545526
Maternal exposure during pregnancy 72.53 13.54 8 31870 159770 50413476
Rash pruritic 66.58 13.54 113 31765 47733 50525513
Forced expiratory volume decreased 61.72 13.54 37 31841 4357 50568889
Exposure during pregnancy 60.52 13.54 4 31874 121011 50452235
Rebound acid hypersecretion 59.08 13.54 17 31861 294 50572952
Completed suicide 58.86 13.54 7 31871 131882 50441364
Peak expiratory flow rate decreased 56.19 13.54 19 31859 569 50572677
Pemphigus 54.56 13.54 6 31872 120160 50453086
Asthma 51.52 13.54 148 31730 89189 50484057
Glossodynia 47.20 13.54 8 31870 115561 50457685
Cervix neoplasm 46.53 13.54 13 31865 201 50573045
Frustration tolerance decreased 46.18 13.54 34 31844 5640 50567606
Drug interaction 46.12 13.54 35 31843 199586 50373660
Headache 45.09 13.54 502 31376 506033 50067213
Obstructive airways disorder 44.35 13.54 52 31826 15600 50557646
Red blood cell sedimentation rate increased 44.30 13.54 72 31806 29344 50543902
Loss of personal independence in daily activities 43.27 13.54 119 31759 69931 50503315
Arteriovenous fistula occlusion 43.24 13.54 14 31864 365 50572881
Arthritis 42.78 13.54 136 31742 86585 50486661
Blue toe syndrome 42.30 13.54 14 31864 392 50572854
Tubulointerstitial nephritis 42.22 13.54 50 31828 15161 50558085
Sputum discoloured 42.18 13.54 47 31831 13348 50559898
Renal failure 41.90 13.54 155 31723 106478 50466768
Somatic delusion 41.45 13.54 15 31863 551 50572695
Peripheral swelling 41.36 13.54 246 31632 205690 50367556
Blood pressure fluctuation 41.35 13.54 78 31800 35745 50537501
Erythema 39.70 13.54 190 31688 146224 50427022
Joint injury 39.35 13.54 58 31820 21731 50551515
Toxicity to various agents 38.85 13.54 46 31832 212453 50360793
Drug specific antibody 38.28 13.54 20 31858 1805 50571441
Chromaturia 37.29 13.54 46 31832 14544 50558702
Endometriosis 36.78 13.54 26 31852 4049 50569197
Faeces soft 36.72 13.54 26 31852 4058 50569188
Hyponatraemia 36.41 13.54 8 31870 96131 50477115
Thrombocytopenia 35.54 13.54 18 31860 127655 50445591
Rhinorrhoea 35.26 13.54 91 31787 51492 50521754
Granuloma 34.86 13.54 27 31851 4831 50568415
Body temperature decreased 34.57 13.54 47 31831 16348 50556898
Cough 33.96 13.54 264 31614 241000 50332246
Respiration abnormal 33.69 13.54 27 31851 5075 50568171
Musculoskeletal stiffness 33.58 13.54 165 31713 128316 50444930
Systemic lupus erythematosus 33.31 13.54 24 31854 140598 50432648
Lung diffusion test decreased 33.19 13.54 13 31865 596 50572650
Swelling 33.09 13.54 47 31831 200825 50372421
Pancytopenia 31.81 13.54 7 31871 84023 50489223
Neutropenia 31.60 13.54 28 31850 147937 50425309
Blood pressure diastolic decreased 30.77 13.54 45 31833 16736 50556510
Drug tolerance 30.05 13.54 25 31853 4951 50568295
Pulmonary thrombosis 30.05 13.54 30 31848 7511 50565735
Bradycardia 29.79 13.54 3 31875 64423 50508823
Central obesity 29.76 13.54 14 31864 1008 50572238
Total lung capacity decreased 29.54 13.54 15 31863 1276 50571970
Confusional state 29.16 13.54 45 31833 185883 50387363
Hypertensive nephropathy 28.49 13.54 11 31867 485 50572761
Gastrooesophageal reflux disease 28.27 13.54 109 31769 76319 50496927
Hand deformity 28.07 13.54 14 31864 100185 50473061
Bronchopulmonary aspergillosis allergic 27.72 13.54 14 31864 1177 50572069
Dysphonia 26.98 13.54 69 31809 38823 50534423
Therapeutic reaction time decreased 26.05 13.54 14 31864 1338 50571908
Gastritis fungal 25.77 13.54 7 31871 97 50573149
Death 25.42 13.54 112 31766 325267 50247979
Forced vital capacity decreased 24.69 13.54 12 31866 929 50572317
Aspartate aminotransferase increased 24.69 13.54 106 31772 77892 50495354
Connective tissue inflammation 24.54 13.54 6 31872 53 50573193
Cardiac arrest 24.49 13.54 11 31867 83640 50489606
Defaecation disorder 24.06 13.54 10 31868 535 50572711
Parotid gland enlargement 24.03 13.54 11 31867 744 50572502
Gastrointestinal motility disorder 23.86 13.54 21 31857 4488 50568758
Hepatic enzyme increased 23.76 13.54 31 31847 137349 50435897
No adverse event 23.73 13.54 60 31818 33518 50539728
Lung opacity 23.61 13.54 15 31863 1958 50571288
Renal pain 23.59 13.54 23 31855 5596 50567650
Urine odour abnormal 22.57 13.54 22 31856 5351 50567895
Echocardiogram abnormal 22.46 13.54 12 31866 1133 50572113
Peak expiratory flow rate abnormal 22.44 13.54 6 31872 78 50573168
Gastric disorder 22.15 13.54 54 31824 29494 50543752
Drug tolerance decreased 22.00 13.54 28 31850 9132 50564114
Renal haemangioma 22.00 13.54 5 31873 31 50573215
Crepitations 21.63 13.54 23 31855 6196 50567050
Cardio-respiratory arrest 21.41 13.54 4 31874 53888 50519358
Bladder disorder 21.27 13.54 25 31853 7518 50565728
Abnormal faeces 21.12 13.54 19 31859 4177 50569069
Abdominal pain 20.85 13.54 234 31644 235994 50337252
Allergy to chemicals 20.77 13.54 12 31866 1320 50571926
Regurgitation 20.65 13.54 12 31866 1334 50571912
Rheumatoid lung 20.58 13.54 15 31863 2450 50570796
Pericarditis 20.57 13.54 12 31866 78677 50494569
Nephrogenic anaemia 20.49 13.54 13 31865 1692 50571554
Parapsoriasis 20.47 13.54 6 31872 111 50573135
Hyperkalaemia 20.37 13.54 3 31875 48086 50525160
Depressed level of consciousness 20.33 13.54 4 31874 51949 50521297
Acute kidney injury 20.16 13.54 226 31652 227832 50345414
Respiratory failure 19.77 13.54 17 31861 91164 50482082
Oropharyngeal pain 19.66 13.54 99 31779 77702 50495544
Patella fracture 19.57 13.54 13 31865 1829 50571417
Blood pressure systolic decreased 19.57 13.54 21 31857 5718 50567528
Coma 19.12 13.54 6 31872 56873 50516373
Musculoskeletal disorder 19.06 13.54 37 31841 17312 50555934
Lung diffusion disorder 18.92 13.54 5 31873 62 50573184
Nausea 18.89 13.54 579 31299 704819 49868427
Brain hypoxia 18.74 13.54 8 31870 458 50572788
Nocturia 18.47 13.54 22 31856 6708 50566538
Electrocardiogram QT prolonged 18.31 13.54 5 31873 51881 50521365
Carcinoid tumour 18.30 13.54 7 31871 301 50572945
Dry throat 18.28 13.54 20 31858 5564 50567682
Platelet count decreased 18.18 13.54 22 31856 100704 50472542
Wound 18.16 13.54 24 31854 105770 50467476
Antinuclear antibody positive 18.04 13.54 21 31857 6251 50566995
Abdominal pain upper 17.97 13.54 166 31712 159143 50414103
Cardiac failure 17.97 13.54 13 31865 76027 50497219
Nephropathy 17.51 13.54 19 31859 5239 50568007
Nasopharyngitis 17.42 13.54 192 31686 192735 50380511
Alanine aminotransferase increased 17.34 13.54 105 31773 88254 50484992
Disease progression 17.23 13.54 21 31857 95845 50477401
Insomnia 17.17 13.54 177 31701 174688 50398558
Neutrophil count decreased 17.08 13.54 4 31874 46022 50527224
Blood pressure diastolic abnormal 17.01 13.54 25 31853 9336 50563910
Influenza 16.69 13.54 105 31773 89433 50483813
Pulmonary embolism 16.53 13.54 24 31854 101680 50471566
Upper respiratory tract infection 16.05 13.54 83 31795 65815 50507431
Dry mouth 16 13.54 74 31804 56104 50517142
Therapy non-responder 15.88 13.54 69 31809 50953 50522293
Nasal congestion 15.81 13.54 69 31809 51051 50522195
Migraine 15.76 13.54 91 31787 75189 50498057
Thoracic operation 15.68 13.54 5 31873 124 50573122
Malignant neoplasm progression 15.64 13.54 12 31866 68112 50505134
Knee deformity 15.34 13.54 9 31869 1018 50572228
Impaired healing 15.14 13.54 13 31865 69773 50503473
Pyrexia 15.06 13.54 160 31718 380043 50193203
C-reactive protein increased 15.01 13.54 82 31796 66392 50506854
Humidity intolerance 14.92 13.54 6 31872 295 50572951
Suicide attempt 14.83 13.54 7 31871 51725 50521521
Injection site oedema 14.79 13.54 9 31869 1089 50572157
Blood test abnormal 14.77 13.54 26 31852 11293 50561953
Mononeuropathy 14.59 13.54 5 31873 156 50573090
Flail chest 14.56 13.54 4 31874 58 50573188
Urinary tract disorder 14.46 13.54 12 31866 2368 50570878
Muscle strain 14.46 13.54 20 31858 7068 50566178
Hyperchlorhydria 14.37 13.54 10 31868 1518 50571728
Heart rate decreased 14.27 13.54 53 31825 36444 50536802
Lung perforation 14.08 13.54 4 31874 66 50573180
Oral discomfort 13.98 13.54 21 31857 7996 50565250
Mucosal inflammation 13.92 13.54 4 31874 40138 50533108
Pharyngitis streptococcal 13.86 13.54 22 31856 8786 50564460
International normalised ratio increased 13.73 13.54 5 31873 43147 50530099
Diarrhoea 13.64 13.54 475 31403 588001 49985245

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 531.51 19.14 250 9200 36166 29528911
End stage renal disease 226.44 19.14 87 9363 7577 29557500
Renal injury 179.60 19.14 80 9370 10122 29554955
Tenosynovitis 149.42 19.14 53 9397 3680 29561397
Enthesopathy 145.49 19.14 52 9398 3691 29561386
C-reactive protein abnormal 114.18 19.14 51 9399 6485 29558592
Tongue disorder 113.63 19.14 46 9404 4590 29560487
Synovitis 100.44 19.14 55 9395 10835 29554242
Tendonitis 95.66 19.14 48 9402 7913 29557164
Alanine aminotransferase abnormal 92.43 19.14 35 9415 2922 29562155
Psoriatic arthropathy 85.18 19.14 55 9395 14636 29550441
Loss of personal independence in daily activities 78.43 19.14 65 9385 25375 29539702
Drug intolerance 52.86 19.14 71 9379 48308 29516769
Headache 50.99 19.14 146 9304 173861 29391216
Occupational dermatitis 49.48 19.14 10 9440 72 29565005
Treatment failure 44.67 19.14 57 9393 36882 29528195
Red blood cell sedimentation rate 43.04 19.14 13 9437 541 29564536
Inspiratory capacity abnormal 41.89 19.14 9 9441 90 29564987
Incorrect product administration duration 41.69 19.14 22 9428 4019 29561058
Oesophageal polyp 41.44 19.14 8 9442 44 29565033
Nerve degeneration 41.16 19.14 10 9440 179 29564898
Granuloma skin 41.03 19.14 13 9437 635 29564442
Nephrogenic anaemia 39.55 19.14 17 9433 1968 29563109
Occupational exposure to air contaminants 39.45 19.14 9 9441 121 29564956
Blood parathyroid hormone decreased 37.97 19.14 13 9437 811 29564266
Asthma 37.45 19.14 50 9400 33799 29531278
Stiff person syndrome 36.97 19.14 8 9442 83 29564994
Renal failure 36.12 19.14 101 9349 118498 29446579
Drug hypersensitivity 35.82 19.14 72 9378 68334 29496743
Mobility decreased 34.72 19.14 42 9408 25738 29539339
Blood immunoglobulin E increased 33.37 19.14 15 9435 1932 29563145
Airway remodelling 33.15 19.14 8 9442 139 29564938
Drug interaction 33.01 19.14 11 9439 197374 29367703
Panniculitis 32.98 19.14 13 9437 1208 29563869
Neck pain 32.29 19.14 37 9413 21410 29543667
Device dislocation 31.39 19.14 19 9431 4508 29560569
Erythema 29.82 19.14 71 9379 75535 29489542
Terminal insomnia 29.16 19.14 9 9441 403 29564674
Rheumatoid nodule 29.07 19.14 14 9436 2108 29562969
Micturition urgency 29.07 19.14 19 9431 5154 29559923
Device malfunction 28.86 19.14 23 9427 8484 29556593
Hypertensive nephropathy 28.74 19.14 9 9441 423 29564654
Erythema of eyelid 28.54 19.14 10 9440 668 29564409
Occupational exposure to product 27.21 19.14 8 9442 303 29564774
Renal haemangioma 27.21 19.14 5 9445 20 29565057
Renal neoplasm 26.92 19.14 11 9439 1122 29563955
Renal mass 26.83 19.14 12 9438 1528 29563549
Bone density decreased 25.83 19.14 12 9438 1668 29563409
Aspartate aminotransferase increased 25.64 19.14 58 9392 59667 29505410
Pain 25.26 19.14 115 9335 171317 29393760
Acute kidney injury 24.82 19.14 157 9293 265110 29299967
Dyspnoea at rest 23.61 19.14 14 9436 3200 29561877
Therapy non-responder 23.12 19.14 38 9412 30873 29534204
Abdominal rigidity 22.81 19.14 10 9440 1214 29563863
Hip surgery 22.70 19.14 9 9441 849 29564228
Contraindicated product administered 21.77 19.14 28 9422 18238 29546839
Chronic kidney disease-mineral and bone disorder 21.54 19.14 7 9443 371 29564706
Alanine aminotransferase increased 21.14 19.14 60 9390 70884 29494193
Restrictive pulmonary disease 20.57 19.14 9 9441 1087 29563990
Rebound acid hypersecretion 20.25 19.14 5 9445 96 29564981
Blood pressure diastolic increased 19.40 19.14 13 9437 3673 29561404
Dermatitis contact 19.32 19.14 12 9438 2980 29562097
Neutropenia 19.26 19.14 9 9441 131702 29433375

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 662.84 14.15 403 34197 57516 64406616
Tenosynovitis 337.37 14.15 152 34448 11681 64452451
Enthesopathy 333.87 14.15 142 34458 9496 64454636
Tongue disorder 272.56 14.15 132 34468 11948 64452184
Tendonitis 236.49 14.15 143 34457 20139 64443993
End stage renal disease 228.92 14.15 112 34488 10363 64453769
Blood parathyroid hormone decreased 211.15 14.15 95 34505 7271 64456861
Red blood cell sedimentation rate 202.82 14.15 76 34524 3638 64460494
Panniculitis 197.22 14.15 96 34504 8783 64455349
Rheumatoid nodule 192.27 14.15 106 34494 12545 64451587
Alanine aminotransferase abnormal 188.47 14.15 86 34514 6802 64457330
Granuloma skin 182.62 14.15 81 34519 5993 64458139
Psoriatic arthropathy 178.16 14.15 163 34437 43118 64421014
C-reactive protein abnormal 167.96 14.15 133 34467 28914 64435218
Skin necrosis 154.19 14.15 96 34504 14233 64449899
Renal injury 147.67 14.15 96 34504 15333 64448799
Blood pressure systolic increased 143.61 14.15 154 34446 49299 64414833
Ulcer 136.64 14.15 107 34493 22883 64441249
Loss of personal independence in daily activities 118.50 14.15 169 34431 72285 64391847
Fear of injection 113.78 14.15 58 34542 5854 64458278
Skin ulcer 103.85 14.15 123 34477 43851 64420281
Basal cell carcinoma 102.02 14.15 103 34497 30735 64433397
Headache 99.87 14.15 552 34048 528915 63935217
Inflammation 94.76 14.15 144 34456 65156 64398976
Hypercalcaemia 91.47 14.15 98 34502 31318 64432814
Drug interaction 89.80 14.15 41 34559 362042 64102090
Rash pruritic 89.61 14.15 131 34469 57273 64406859
Asthma 85.69 14.15 170 34430 95055 64369077
Toxicity to various agents 82.89 14.15 46 34554 363467 64100665
Total lung capacity increased 80.06 14.15 25 34575 683 64463449
Drug eruption 78.66 14.15 97 34503 36039 64428093
Erythema 74.34 14.15 245 34355 186825 64277307
Peripheral swelling 62.77 14.15 250 34350 208903 64255229
Peak expiratory flow rate decreased 57.96 14.15 19 34581 609 64463523
Thrombocytopenia 55.96 14.15 25 34575 223776 64240356
Drug abuse 55.57 14.15 4 34596 132370 64331762
Forced expiratory volume decreased 54.38 14.15 38 34562 6829 64457303
Synovitis 53.79 14.15 145 34455 98945 64365187
Hyponatraemia 53.27 14.15 8 34592 148331 64315801
Rhinorrhoea 51.45 14.15 105 34495 59864 64404268
Aspartate aminotransferase increased 51.27 14.15 161 34439 119627 64344505
Red blood cell sedimentation rate increased 51.24 14.15 73 34527 31162 64432970
Neutropenia 50.81 14.15 33 34567 239591 64224541
Cervix neoplasm 50.13 14.15 13 34587 177 64463955
Drug hypersensitivity 50.11 14.15 256 34344 237559 64226573
Drug intolerance 48.80 14.15 215 34385 187777 64276355
Frustration tolerance decreased 48.75 14.15 34 34566 6091 64458041
Endometriosis 46.88 14.15 25 34575 2767 64461365
Blood pressure diastolic decreased 45.55 14.15 58 34542 22243 64441889
Occupational dermatitis 44.58 14.15 11 34589 121 64464011
Pancytopenia 44.55 14.15 11 34589 143298 64320834
Joint injury 44.24 14.15 58 34542 22889 64441243
Nephrogenic anaemia 42.80 14.15 25 34575 3300 64460832
Multiple organ dysfunction syndrome 42.75 14.15 3 34597 101410 64362722
Gastrooesophageal reflux disease 42.46 14.15 119 34481 83024 64381108
Somatic delusion 40.90 14.15 15 34585 675 64463457
Sputum discoloured 40.58 14.15 49 34551 17807 64446325
Arteriovenous fistula occlusion 40.36 14.15 14 34586 535 64463597
Blue toe syndrome 39.65 14.15 14 34586 564 64463568
Drug specific antibody 38.71 14.15 20 34580 2075 64462057
Alanine aminotransferase increased 38.36 14.15 162 34438 138869 64325263
Rebound acid hypersecretion 37.81 14.15 9 34591 84 64464048
Blood pressure fluctuation 37.79 14.15 85 34515 51786 64412346
Maternal exposure during pregnancy 37.25 14.15 4 34596 95880 64368252
Therapy non-responder 36.32 14.15 97 34503 65802 64398330
Death 36.24 14.15 135 34465 482570 63981562
Cardiac arrest 35.77 14.15 19 34581 154045 64310087
Cough 35.35 14.15 280 34320 301868 64162264
Fatigue 34.86 14.15 579 34021 748151 63715981
Obstructive airways disorder 34.85 14.15 52 34548 23133 64440999
Occupational exposure to air contaminants 34.81 14.15 9 34591 121 64464011
Respiration abnormal 34.53 14.15 28 34572 6287 64457845
Respiratory failure 34.41 14.15 22 34578 161161 64302971
Arthritis 34.34 14.15 111 34489 83703 64380429
Drug tolerance decreased 34.05 14.15 29 34571 6969 64457163
Nasopharyngitis 33.84 14.15 200 34400 195873 64268259
Cardio-respiratory arrest 33.77 14.15 6 34594 98387 64365745
Granuloma 33.30 14.15 28 34572 6613 64457519
Completed suicide 33.20 14.15 43 34557 224371 64239761
Hyperkalaemia 32.95 14.15 7 34593 101122 64363010
Inspiratory capacity abnormal 32.84 14.15 8 34592 83 64464049
Dysphonia 32.67 14.15 75 34525 46307 64417825
Nerve degeneration 32.46 14.15 10 34590 261 64463871
Sepsis 32.20 14.15 46 34554 230295 64233837
Faeces soft 32.10 14.15 26 34574 5829 64458303
Oesophageal polyp 30.83 14.15 7 34593 52 64464080
Coma 30.82 14.15 5 34595 87610 64376522
Rhabdomyolysis 30.61 14.15 6 34594 91720 64372412
Musculoskeletal stiffness 30.50 14.15 139 34461 123067 64341065
Arthralgia 30.16 14.15 366 34234 441894 64022238
Pulmonary thrombosis 29.19 14.15 32 34568 10486 64453646
Platelet count decreased 28.19 14.15 29 34571 167682 64296450
Neutrophil count decreased 28.08 14.15 4 34596 77192 64386940
Depressed level of consciousness 27.87 14.15 5 34595 81431 64382701
Hypertensive nephropathy 27.82 14.15 12 34588 829 64463303
Total lung capacity decreased 27.74 14.15 15 34585 1707 64462425
Nausea 27.32 14.15 581 34019 785219 63678913
C-reactive protein increased 27.27 14.15 112 34488 94797 64369335
Defaecation disorder 27.20 14.15 10 34590 453 64463679
Cardiac failure 27 14.15 19 34581 132354 64331778
Treatment failure 26.87 14.15 129 34471 116687 64347445
Lung diffusion test decreased 26.76 14.15 13 34587 1183 64462949
Body temperature decreased 26.63 14.15 49 34551 25879 64438253
Oropharyngeal pain 26.43 14.15 106 34494 88761 64375371
Renal pain 26.24 14.15 25 34575 6949 64457183
Bronchopulmonary aspergillosis allergic 25.77 14.15 14 34586 1608 64462524
Confusional state 25.26 14.15 65 34535 261079 64203053
Drug tolerance 25.18 14.15 23 34577 6062 64458070
Rheumatoid lung 25.13 14.15 16 34584 2463 64461669
Pyrexia 24.68 14.15 187 34413 558457 63905675
Stiff person syndrome 24.48 14.15 8 34592 254 64463878
Drug ineffective 24.46 14.15 606 33994 839641 63624491
Occupational exposure to product 24.40 14.15 10 34590 608 64463524
Disease progression 24.38 14.15 24 34576 141656 64322476
Central obesity 24.35 14.15 13 34587 1442 64462690
Abdominal pain upper 24.30 14.15 169 34431 174861 64289271
Incorrect product administration duration 24.20 14.15 28 34572 9730 64454402
Rheumatoid arthritis 23.62 14.15 160 34440 164134 64299998
Crepitations 23.58 14.15 25 34575 7890 64456242
Therapeutic reaction time decreased 23.49 14.15 14 34586 1918 64462214
Pain in extremity 23.39 14.15 257 34343 302828 64161304
Peak expiratory flow rate abnormal 23.32 14.15 6 34594 79 64464053
Abdominal pain 23.25 14.15 263 34337 312112 64152020
Airway remodelling 23.24 14.15 7 34593 169 64463963
Pain 23.14 14.15 421 34179 553090 63911042
Electrocardiogram QT prolonged 22.99 14.15 7 34593 79441 64384691
Lactic acidosis 22.77 14.15 3 34597 61407 64402725
Musculoskeletal disorder 22.51 14.15 37 34563 17869 64446263
Urine odour abnormal 22.40 14.15 20 34580 5116 64459016
Allergy to chemicals 22.39 14.15 11 34589 1026 64463106
Blood test abnormal 22.34 14.15 31 34569 12912 64451220
Gastrointestinal motility disorder 22.26 14.15 20 34580 5159 64458973
Renal failure 22.11 14.15 170 34430 181518 64282614
Delirium 22.11 14.15 5 34595 69189 64394943
Pulmonary embolism 21.68 14.15 28 34572 146328 64317804
Lung opacity 21.44 14.15 16 34584 3183 64460949
Blood pressure systolic decreased 21.35 14.15 25 34575 8795 64455337
Blood pressure diastolic abnormal 21.25 14.15 29 34571 11888 64452244
International normalised ratio increased 21.13 14.15 8 34592 79159 64384973
Forced vital capacity decreased 21.12 14.15 12 34588 1504 64462628
Chromaturia 21.08 14.15 41 34559 22570 64441562
Patella fracture 20.67 14.15 12 34588 1566 64462566
Infusion related reaction 20.64 14.15 155 34445 164312 64299820
Device dependence 20.60 14.15 5 34595 51 64464081
Blood pressure diastolic increased 20.45 14.15 27 34573 10725 64453407
Bradycardia 20.37 14.15 20 34580 118199 64345933
Carcinoid tumour 20.28 14.15 8 34592 440 64463692
Abnormal faeces 20.16 14.15 20 34580 5839 64458293
Terminal insomnia 20.14 14.15 10 34590 954 64463178
Hypotension 20.05 14.15 121 34479 380853 64083279
Renal neoplasm 19.96 14.15 12 34588 1669 64462463
Heart rate decreased 19.96 14.15 70 34530 54997 64409135
Intentional overdose 19.57 14.15 12 34588 89932 64374200
Anaemia 19.55 14.15 121 34479 378559 64085573
Hypokalaemia 19.46 14.15 22 34578 121881 64342251
Chronic kidney disease-mineral and bone disorder 19.26 14.15 8 34592 503 64463629
Metabolic acidosis 19.23 14.15 7 34593 70951 64393181
Heart rate increased 19.21 14.15 104 34496 98571 64365561
Seizure 19.00 14.15 38 34562 166854 64297278
Bone density decreased 18.94 14.15 25 34575 9927 64454205
Ear infection 18.92 14.15 40 34560 23364 64440768
Bladder disorder 18.78 14.15 22 34578 7745 64456387
Therapeutic product effect incomplete 18.77 14.15 107 34493 103375 64360757
Hyperparathyroidism secondary 18.70 14.15 13 34587 2317 64461815
Respiratory arrest 18.69 14.15 3 34597 52982 64411150
Wheezing 18.53 14.15 89 34511 80490 64383642
Gastritis fungal 18.46 14.15 6 34594 187 64463945
Erythema of eyelid 18.23 14.15 12 34588 1956 64462176
Hypoglycaemia 18.20 14.15 13 34587 89879 64374253
Gastric disorder 18.17 14.15 45 34555 29152 64434980
Blood pressure increased 18.05 14.15 156 34444 172396 64291736
Muscle strain 17.83 14.15 22 34578 8172 64455960
Knee deformity 17.74 14.15 9 34591 899 64463233
Systemic lupus erythematosus 17.39 14.15 10 34590 77602 64386530
Product use issue 17.38 14.15 140 34460 151575 64312557
Medication error 17.24 14.15 3 34597 49963 64414169
Therapeutic response shortened 17.01 14.15 24 34576 10146 64453986
Septic shock 16.86 14.15 19 34581 105418 64358714
Echocardiogram abnormal 16.79 14.15 11 34589 1778 64462354
Lung diffusion disorder 16.79 14.15 5 34595 116 64464016
Mental status changes 16.63 14.15 6 34594 61156 64402976
Dyspepsia 16.56 14.15 86 34514 80226 64383906
Gamma-glutamyltransferase increased 16.55 14.15 3 34597 48507 64415625
Pemphigus 16.42 14.15 6 34594 60695 64403437
Respiratory distress 16.29 14.15 4 34596 52327 64411805
Injection site oedema 16.27 14.15 9 34591 1071 64463061
Suicide attempt 16.12 14.15 9 34591 70998 64393134
Oral discomfort 15.82 14.15 21 34579 8385 64455747
Heart rate irregular 15.76 14.15 41 34559 27372 64436760
Migraine 15.71 14.15 71 34529 62606 64401526
Neck pain 15.65 14.15 70 34530 61463 64402669
Dry throat 15.65 14.15 18 34582 6214 64457918
Tubulointerstitial nephritis 15.53 14.15 44 34556 30865 64433267
Cardiac failure congestive 15.50 14.15 29 34571 130551 64333581
Haematocrit decreased 15.48 14.15 5 34595 54650 64409482
Influenza 15.45 14.15 104 34496 106427 64357705
Unresponsive to stimuli 15.40 14.15 4 34596 50389 64413743
Ascites 15.36 14.15 7 34593 61994 64402138
Pharyngitis streptococcal 15.32 14.15 21 34579 8647 64455485
Nasal congestion 15.27 14.15 68 34532 59590 64404542
Mobility decreased 15.07 14.15 88 34512 85752 64378380
Humidity intolerance 15.06 14.15 6 34594 339 64463793
Thoracic operation 15.00 14.15 5 34595 169 64463963
Glossodynia 14.98 14.15 8 34592 64688 64399444
Renal mass 14.64 14.15 12 34588 2735 64461397
Lung perforation 14.55 14.15 4 34596 69 64464063
Blood alkaline phosphatase increased 14.50 14.15 6 34594 56273 64407859
Renal haemangioma 14.40 14.15 3 34597 14 64464118
Flail chest 14.33 14.15 4 34596 73 64464059
Stomatitis 14.23 14.15 23 34577 109582 64354550
Acute myocardial infarction 14.22 14.15 10 34590 69708 64394424
Pneumonia aspiration 14.21 14.15 7 34593 59264 64404868

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BC06 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Proton pump inhibitors
FDA MoA N0000000147 Proton Pump Inhibitors
FDA EPC N0000175525 Proton Pump Inhibitor
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D054328 Proton Pump Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Erosive esophagitis indication 40719004
Gastroesophageal reflux disease indication 235595009 DOID:8534
Maintenance of Healing Erosive Esophagitis indication
Duodenal ulcer disease off-label use 51868009 DOID:1724
Zollinger-Ellison syndrome off-label use 53132006 DOID:0050782
Gastric ulcer off-label use 397825006 DOID:10808
Duodenal Ulcer due to H. Pylori off-label use
Maintenance of Healing Duodenal Ulcer off-label use
NSAID-Induced Gastric Ulcer off-label use
Prevention of NSAID-Induced Gastric Ulcer off-label use
Pathological Gastric Hypersecretory Condition off-label use
Osteoporosis contraindication 64859006 DOID:11476
Fracture of bone contraindication 125605004
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.23 acidic
pKa2 3.35 Basic
pKa3 2.72 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG DEXILANT SOLUTAB TAKEDA PHARMS USA N208056 Jan. 26, 2016 DISCN TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG DEXILANT SOLUTAB TAKEDA PHARMS USA N208056 Jan. 26, 2016 DISCN TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 9233103 March 5, 2032 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 9233103 March 5, 2032 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium-transporting ATPase Transporter INHIBITOR CHEMBL CHEMBL
Cytosolic endo-beta-N-acetylglucosaminidase Enzyme IC50 4.60 CHEMBL
Sterile alpha and TIR motif-containing protein 1 Unclassified IC50 5.48 CHEMBL

External reference:

IDSource
4028570 VUID
N0000189452 NUI
D08903 KEGG_DRUG
313640-86-7 SECONDARY_CAS_RN
4028570 VANDF
C2348248 UMLSCUI
CHEBI:135931 CHEBI
CHEMBL1201863 ChEMBL_ID
D064748 MESH_DESCRIPTOR_UI
DB05351 DRUGBANK_ID
5487 IUPHAR_LIGAND_ID
8524 INN_ID
UYE4T5I70X UNII
9578005 PUBCHEM_CID
816346 RXNORM
160770 MMSL
172755 MMSL
26184 MMSL
356045 MMSL
d07395 MMSL
012953 NDDF
441863009 SNOMEDCT_US
442540007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-703 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-703 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-704 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-704 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 50090-4374 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 32 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 50090-5944 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 50090-5956 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Kapidex HUMAN PRESCRIPTION DRUG LABEL 1 54868-5998 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA 16 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 54868-6152 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 31 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 55154-5154 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 31 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-171 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-171 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-175 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-175 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 33 sections